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Short Communication
Plasma fibroblast growth factor-21 levels in patients with inborn errors of
metabolism☆
Brian Kirmseb,⁎, Juan Cabrerra-Luquea, Omar Ayyuba, Kristina Cusmanoa, Kimberly Chapmana,
Marshall Summara
a Children's National Health System, Division of Genetics &Metabolism, Washington, DC, United States
b University of Mississippi Medical Center, Department of Pediatrics, Jackson, MS, United States
A B S T R A C T
Fibroblast growth factor-21 (FGF21) levels are elevated in patients with primary mitochondrial disorders but
have not been studied in patients with inborn errors of metabolism (IEM) known to have secondary
mitochondrial dysfunction. We measured plasma FGF21 by ELISA in patients with and without IEM. FGF21
levels were higher in patients with IEM compared to without IEM (370 pg/dL vs. 0–65 pg/dL). Further study of
FGF21 as a biomarker in IEM is warranted.
1. Background
Secondary mitochondrial dysfunction is observed as a consequence
of dysfunction in pathways of intermediary metabolism. A well-known
example occurs in acute metabolic decompensations in patients with
organic acidurias (OA) and fat oxidation disorders (FAOD) which are
often characterized by hyperlactatemia and the urinary excretion of
mitochondrial and Kreb's cycle metabolites [1]. Speculation about the
mechanism of secondary mitochondrial dysfunction in some inborn
errors of metabolism (IEM) has revolved around the depletion of the
Coenzyme-A pools subsequent to the overproduction of organic and
dicarboxylic acids, a paucity of Kreb's cycle intermediates or direct
effects on oxidative phosphorylation (OXPHOS) by elevated levels of
cytotoxic intermediates [6]. Moreover, mitochondrial oxidative stress
has been implicated as a pathological factor in a broader range of IEM
including urea cycle disorders and phenylketonuria [4,7]. There is little
known about how mitochondrial energy production is regulated in IEM
patients in the bioenergetically balanced or decompensated states
despite the fact that it has long been implicated in the group's
pathological manifestations.
Fibroblast growth factor 21 (FGF21) is an important hepatokine in
both intermediary and mitochondrial energy metabolism. FGF21 has
been shown to stimulate fatty acid oxidation and ketogenesis, reduce
insulin secretion, increase insulin sensitivity and inhibit overall growth
through PPAR-gamma and beta-Klotho signaling pathways on multiple
tissue types, including the brain, adipose and muscle [5]. Additionally,
FGF21 may modulate OXPHOS through AMPK and SIRT1 activation
[2].
Irrespective of its actions on metabolism, FGF21 has recently been
proposed as a clinical biomarker for primary mitochondrial disorders,
in particular those that manifest as myopathy [3]. In one study by [8],
FGF21 levels were more sensitive and specific than traditional biomar-
kers of mitochondrial dysfunction such as creatine kinase, lactate and
pyruvate. Given that FGF21 levels are elevated in primary mitochon-
drial disorders and many IEM demonstrate secondary mitochondrial
dysfunction we hypothesized FGF21 levels would be significantly
higher in patients with IEM.
2. Methods
2.1. Study population
After approval from the Children's National Office for the Protection
of Human Subjects, plasma samples were collected from patients with
diagnosed IEM (n = 42) seen for health supervision (well) visits in the
Metabolic Disorders Clinic at Children's National, Washington, DC.
Control samples (n= 7) were from de-identified, waste plasma samples
from patients without a known IEM and were collected and analyzed at
the same time as the IEM patients' samples.
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2.2. FGF21 levels
FGF21 levels were determined in plasma of patients and control
samples using the Human FGF-21 ELISA kit from BioVendor (Cat#
RD191108200R) following manufacturer's recommendations. The low-
er limit of detection for the assay was 30 pg/mL. Leucine (Leu) and
phenylalanine (Phe) levels were measured for clinical care using a
Biochrom 30 analyzer in a CLIA certified lab as previously described.
Statistical analysis was done using GraphPad Prism (v7). Averages were
calculated for groups (Controls, IEM, mitochondrial IEM and non-
mitochondrial IEM, Leu and Phe levels). Correlation between Leu and
FGF21 levels was tested by calculating the Pearson coefficient.
3. Results
The study population included 7 control patients without IEM, 4
with respiratory chain complex 1 deficiency, 6 with urea cycle disorders
(1 orinithine transcarbamylase deficiency, 1 carbamoyl phosphate
synthase-1 deficiency, 1 citrullinemia, 2 arginosuccinate lyase defi-
ciency, 1 with proximal UCD that had not been molecularly character-
ized), 4 fatty acid oxidation disorder (2 very-long chain acyl-CoA
dehydrogenase deficiency, 2 carnitine palmitoyltransferase-2 defi-
ciency), 7 organic aciduria (4 propionic acidemia, 2 isovaleric aciduria,
1 undiagnosed OA), 6 maple syrup urine disease, 4 phenylketonuria, 7
homocystinuria (3 classic homocystinuria, 2 methionine synthase
deficiency, 1 cobalamin-c disease).
Fig. 1's first panel shows the difference in FGF21 levels between
patients with IEM and those without IEM (370 pg/dL vs. 0–65 pg/dL).
FGF21 levels were not significantly higher in patients with mitochon-
drial IEM (UCD, OA, FAO) compared to non-mitochondrial IEM (PKU,
MSUD, Homocystinuria) (908 pg/dL vs 415 pg/dL). Fig. 1's second
panel shows the distribution of levels by broad categories of IEM.
Because Leu levels are widely accepted by clinicians as markers of
biochemical control in MSUD patients, we looked for a correlation
between Leu and FGF21 levels analyzed from the same plasma sample
(N = 6; r2 = 0.0542, p = 0.1), observing a tendency towards a mod-
erate positive correlation that was not statistically significant. We were
unable to perform the same analysis for the PKU patients due to small
sample size (N = 4), but did note that the PKU patient with the highest
average Phe level (13.8 mg/dL vs 4.8, 7.7 and 9.8 mg/dL) over the year
preceding the FGF21 measurement, had the highest FGF21 level of the
PKU group (1340 pg/mL vs 75, 0 and 0 pg/mL).
4. Discussion
FGF21 levels were generally higher in patients with IEM compared
to unaffected controls and the levels within the IEM group show a high
degree of variability. In this sample's patients with MSUD FGF21 levels
tended to correlate with plasma leucine although this was not a
statistically significant observation. These data suggest that elevation
of FGF21 is a common finding in patients with IEM and that perturba-
tions might potentially correlate with disease severity in some dis-
orders.
The multiple effects of FGF21 on metabolism as well as the multiple
effects of metabolic states (catabolic vs anabolic) on FGF21 levels do
not allow us to easily say why FGF21 levels should be high in IEM
patients. Certainly FGF21 may be elevated for the same reasons they are
postulated to be high in primary mitochondrial disorders, namely that
inefficient energy metabolism leads to a cellular bioenergetic state that
is biochemically similar to starvation [9]. Alternatively, for cases
wherein the dietary management is based on macromolecular restric-
tion (protein in PKU and MSUD, long-chain fat in FAOD) FGF21 levels
could be affected. What speaks against this latter point in our study is
that fact that all of the IEM groups had individuals with elevated FGF21
levels and not all of them are treated with (or adherent to) dietary
restriction.
Further studies of FGF21 in IEM patients are warranted particularly
if FGF21 continues to prove useful as a clinical discriminator of
mitochondrial dysfunction. There are currently very few informative
biomarkers for IEM disease severity, dietary adherence and clinical
outcomes. Future studies of FGF21 in IEM should be larger, disorder-
focused, longitudinal, account for clinical factors such as genotype and
clinical disease severity as well as measure traditional biomarkers
(amino acids, ammonia, etc.) and markers of oxidant stress.
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Fig. 1. FGF21 levels in patient with and without IEM. IEM−= Control subjects without an IEM, IEM+= all subjects with a diagnosed IEM, MITO = known primary mitochondrial
disorder, UCD = Urea Cycle Disorder, MSUD =Maple Syrup Urine Disease, PKU = Phenylketonuria, HCY = Homocystinuria (Classic), FAO = Fatty Acid Oxidation Disorder,
OA = Organic aciduria.
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